Table 3. Current phase III trials of combination therapies in melanoma. Information sourced from ClinicalTrials.gov.

Combinations of pathway inhibitors
ClinicalTrials.gov Identifier	Drug type	Treatment combinations	Indication and inclusion criteria	Status
NCT01584648	BRAF inhibitor + MEK inhibitor	Comparing dabrafenib + trametinibvs.Dabrafenib monotherapy	Stage IIIC (unresectable) or Stage IV BRAF V600E/K-mutant melanomaFirst line treatment	Active, not recruiting
NCT01682083	BRAF inhibitor + MEK inhibitor	Dabrafenib + trametinib vs.placebo	Adjuvant treatment of high risk V600E/K mutation-positive melanoma after surgical resection	Active, not recruiting
NCT01909453	BRAF inhibitor + MEK inhibitor vs. BRAF inhibitor alone	LGX818 + MEK162vs.vemurafenib monotherapyorLGX818 monotherapy	Locally advanced, unresectable or metastatic BRAF V600E/K-mutant melanomaFirst line treatment or second line in patients who have progressed on or after first line immunotherapy	Active, not recruiting
NCT01597908	BRAF inhibitor + MEK inhibitor vs. BRAF inhibitor alone	Dabrafenib + trametenibvs.vemurafenib monotherapy	Stage IIIC (unresectable) or Stage IV BRAF V600E/K-mutant melanomaFirst line treatment	Active, not recruiting
NCT01689519	BRAF inhibitor + MEK inhibitor vs. BRAF inhibitor alone	vemurafenib + cobimetinibvs.vemurafenib monotherapy	Stage IIIC (unresectable) or Stage IV BRAF V600E/K-mutant melanomaFirst line treatment	Active, not recruiting
Combination of pathway inhibitors with immunotherapies
ClinicalTrials.gov Identifier	Drug type	Treatment combinations	Indication and inclusion criteria	Status
NCT02908672	Anti-PDL1 antibody + MEK inhibitor + BRAF inhibitor vs. placebo + MEK inhibitor + BRAF inhibitor	Atezolizumab + cobimetinib + vemurafenibvs.placebo + cobimetinib + vemurafenib	Stage IIIC (unresectable) or Stage IV BRAF V600E/K-mutant melanomaFirst line treatment	Recruiting
NCT02967692	Anti-PD-1 antibody + BRAF inhibitor + MEK inhibitor vs. placebo + BRAF inhibitor + MEK inhibitor	PDR001 + dabrafenib + trametinibvs.placebo + dabrafenib + trametinib	Stage IIIC (unresectable) or Stage IV BRAF V600E/K-mutant melanomaFirst line treatment	Recruiting